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Abstract
Introduction:  Endoscopic  retrograde  cholangiopancreatography  (ERCP)  is  associated  with  an
acute inﬂammatory  response  and  melatonin  has  a  variety  of  immunomodulatory  and  antioxidant
effects studied  experimentally  in  pancreatobiliary  pathology.
Aims:  The  aim  of  our  study  was  to  evaluate  the  effects  of  peri-procedural  administration  of
melatonin on  the  inﬂammatory  response  and  lipid  peroxidation  associated  with  ERCP.
Methods:  In  this  proof-of-concept  clinical  trial,  37  patients  with  a  high  probability  of  chole-Lipid  peroxidation docholithiasis  were  randomized  to  receive  peri-procedure  (ERCP)  melatonin  or  placebo.  We
measured  the  serum  concentration  of  tumor  necrosis  factor-alpha  (TNF-alpha),  interleukin-6
(IL-6), vascular  endothelial  growth  factor  (VEGF),  lipid  peroxidation,  amylase,  and  liver  function
tests 24  h  before  and  after  the  procedure.
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Results:  We  found  no  pre-procedure  or  post-procedure  differences  between  the  melatonin
group or  the  placebo  group  (P>.05)  in  the  serum  concentrations  of  TNF-alpha  (melatonin:
153.8 vs.  149.4  ng/m;  placebo:  103.5  vs.  107.3  ng/ml),  IL-6  (melatonin:  131.8  vs.  133.3  ng/ml;
placebo: 177.8  vs.  197.8  ng/ml),  or  VEGF  (melatonin:  157.3  vs.  157.8  pg/ml;  placebo:  97.3  vs.
97.8 pg/ml),  or  in  relation  to  lipid  peroxidation  (melatonin:  39.2  vs.  72.3  g/ml;  placebo:  66.4
vs. 90.5  g/ml).  After  ERCP,  a  signiﬁcant  decrease  in  the  AST,  ALT,  and  total  bilirubin  levels
was found  only  in  the  melatonin  group  (P<.05).  The  administration  of  melatonin  was  safe  and
tolerable.
Conclusions:  Melatonin  is  safe  and  tolerable  in  patients  undergoing  ERCP,  but  it  does  not  appear
to affect  inﬂammatory  cytokine  concentrations  or  lipid  peroxidation.
© 2016  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Published  by  Masson  Doyma  Me´xico  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Efectos  de  la  melatonina  en  la  respuesta  inﬂamatoria  aguda  asociada  con  la
colangiopancreatografía  retrógrada  endoscópica:  un  ensayo  clínico  aleatorizado,
doble  ciego  y  controlado  con  placebo
Resumen
Introducción:  La  colangiopancreatografía  retrógrada  endoscópica  (CPRE)  está  asociada  con
la generación  de  respuesta  inﬂamatoria  aguda,  la  melatonina  tiene  una  variedad  de  efectos
inmunomoduladores  y  antioxidantes  probados  de  manera  experimental  en  patología  pancrea-
tobiliar.
Objetivo: El  objetivo  del  estudio  fue  evaluar  los  efectos  de  la  administración  periprocedimiento
de melatonina  sobre  la  respuesta  inﬂamatoria  y  peroxidación  lipídica  asociada  a  la  realización
de CPRE.
Métodos:  En  este  ensayo  clínico  se  incluyó  a  37  pacientes  con  riesgo  alto  de  coledocolitia-
sis, se  aleatorizaron  para  recibir  melatonina  o  placebo  periprocedimiento  (CPRE).  Se  midió
la concentración  sérica  de  factor  de  necrosis  tumoral  alfa  (FNT-alfa),  interleucina-6  (IL-6),
factor de  crecimiento  endotelial  vascular  (FCEV),  peroxidación  lipídica,  amilasa  y  pruebas  de
funcionamiento  hepático  24  h  antes  y  después  del  procedimiento.
Resultados:  No  encontramos  diferencia  entre  las  concentraciones  séricas  de  FNT  alfa  (mela-
tonina: 153.8  vs.  149.4  ng/mL;  placebo:  103.5  vs.  107.3  ng/mL),  IL-6  (melatonina:  131.8  vs.
133.3 ng/mL;  placebo:  177.8  vs.  197.8  ng/mL)  y  FCEV  (melatonina:  157.3  vs.  157.8  pg/mL;
placebo: 97.3  vs.  97.8  pg/mL),  o  en  peroxidación  lipídica  (melatonina:  39.2  vs.  72.3  g/mL;
placebo:  66.4  vs.  90.5  g/mL)  preprocedimiento  vs.  posprocedimiento  en  ninguno  de  los  2
grupos (p  >  0.05).  Posterior  a  la  CPRE,  los  niveles  de  aspartato  aminotransferasa,  alanina  amino-
transferasa  y  bilirrubina  total  disminuyeron  signiﬁcativamente  solo  en  el  grupo  de  melatonina
(p <  0.05).  La  administración  de  melatonina  es  segura  y  tolerada.
Conclusiones:  La  melatonina  es  segura  y  tolerada  en  pacientes  que  van  a  CPRE,  pero  no  parece
afectar las  concentraciones  de  citocinas  proinﬂamatorias  o  peroxidación  lipídica  en  humanos.
© 2016  Asociacio´n  Mexicana  de  Gastroenterolog´ıa.  Publicado  por  Masson  Doyma  Me´xico  S.A.
Este es  un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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cute  pancreatitis  (AP)  is  a  feared  complication  of  endo-
copic  retrograde  cholangiopancreatography  (ERCP)  that
an  occur  in  up  to  30%  of  high-risk  patients.1,2 Established
isk  factors  for  post-ERCP  pancreatitis  include  young  age,
emale  sex,  history  of  post-ERCP  pancreatitis,  sphincter  of
ddi  dysfunction,  cannulation  time  >  10  min,  and  passage  of
uidewire  or  contrast  medium  into  the  pancreatic  duct.2,3
phincter  spasm,  edema,  enzymatic  injury,  infection,  or
echanical  manipulation  have  been  proposed  as  potential
a
d
t
cechanisms  responsible  for  post-ERCP  pancreatitis.2,3 The
evelopment  of  an  acute  inﬂammatory  state  and  cytokine
ctivation  could  modulate  these  mechanisms  and  con-
ribute  to  pancreatic  injury.  ERCP  has  been  considered
 useful  model  for  studying  the  acute  phase  response  in
P.3,4 After  ERCP,  elevations  of  amylase  and  inﬂammatory
ytokines,  such  as  tumor  necrosis  factor-alpha  (TNF-alpha)
nd  interleukin-6  (IL-6),  are  common  and  could  predict  the
evelopment  of  AP.4--6 Experimental  studies  have  established
hat  these  cytokines,  as  well  as  a  state  of  oxidative  stress,
ontribute  to  the  pathophysiology  of  AP.7,8
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Clinical  trials  have  demonstrated  that  pancreatic  duct
stent  placement  and  pharmacologic  therapy  with  nonste-
roidal  anti-inﬂammatory  drugs  can  reduce  the  incidence  of
post-ERCP  pancreatitis.9,10 Other  agents  have  been  stud-
ied  as  potential  candidates  for  modulating  the  inﬂammatory
response  and  oxidative  stress  associated  with  ERCP.10,11 How-
ever,  the  search  for  safe  and  effective  alternatives  is  an
active  ﬁeld  of  research.
Melatonin  is  a  multifunctional  endogenous  indolamine
produced  in  the  pineal  gland,  classically  associated  with  reg-
ulation  of  the  circadian  rhythm.  Its  administration  in  humans
is  safe  and  well  tolerated.12 Clinical  and  experimental  stud-
ies  have  shown  that  melatonin  has  potent  anti-inﬂammatory
and  antioxidant  effects,  modulating  TNF-alpha,  IL-6,  and
the  production  of  free  radicals.13--15 Additionally,  a  large
body  of  experimental  evidence  suggests  that  melatonin  can
reduce  pancreatic  injury,  systemic  inﬂammation,  and  oxida-
tive  stress  in  animal  models  of  AP.16,17
The  aim  of  the  present  study  was  to  investigate  the
effects  of  melatonin  on  post-ERCP-induced  hyperamy-
lasemia  and  elevations  in  inﬂammatory  and  oxidative  stress
markers.
Materials and methods
Patients  and  procedures
The  study  design  was  a  randomized,  double-blind,  and
placebo-controlled  clinical  trial.  The  study  protocol  was
approved  by  the  local  ethics  committee,  and  written
informed  consent  was  obtained  from  all  participants  in
accordance  with  the  Declaration  of  Helsinki.  We  included
37  consecutive  patients  admitted  from  March  to  July  2013  at
the  Hospital  Universitario  ‘‘Dr.  José  E.  González’’  in  Nuevo
Leon,  with  suspicion  of  choledocholithiasis  and  scheduled  to
undergo  ERCP.
Suspected  choledocholithiasis  was  considered  when
patients  presented  with  upper  abdominal  pain  and  clinical
manifestations  (e.g.  fever,  jaundice),  a  cholestatic  pattern
of  liver  injury,  common  bile  duct  (CBD)  dilatation  (>  6  mm),
or  CBD  stone  visualization  on  transabdominal  ultrasound
(US).  Study  subjects  were  identiﬁed  upon  admission  by  gas-
troenterology  residents,  based  on  an  assessment  of  clinical,
radiologic,  and  biochemical  variables.
Inclusion  criteria  were  age  above  18  years  and  a  high
probability  of  choledocholithiasis  on  admission,  according
to  the  American  Society  for  Gastrointestinal  Endoscopy
2010  criteria.18 Exclusion  criteria  included  patients  that  had
systemic  inﬂammatory  response  syndrome  (deﬁned  by  the
presence  of  2  or  more  criteria:  heart  rate  >  90  beats/min,
core  temperature  <  36 ◦C  or  >  38 ◦C,  a  white  blood  cell  count
<  4000  or  >  12000/mm3,  a  respiratory  rate  >  20  min),  acute
pancreatitis  or  unresolved  pancreatitis,  cholangitis,  a  his-
tory  of  any  rheumatologic  or  inﬂammatory  disease,  patients
that  were  pregnant  or  breast-feeding,  patients  with  a  his-
tory  of  sensitivity  to  melatonin,  or  those  with  a  history  of
being  intubated  and  on  ventilator  support.ERCPs  were  performed  by  an  experienced  gastroenterol-
ogist  blinded  to  patient  allocation.  The  indication  for  ERCP
in  all  patients  was  a  high  probability  of  choledocholithiasis.
The  development  of  pancreatitis  was  diagnosed  and  graded
i
t
p
tted  with  ERCP  143
ollowing  published  consensus  criteria.9 ERCP  risk  score  for
ost-ERCP  pancreatitis  was  obtained  using  a  validated  tool
ublished  by  Friedland  et  al.19 For  all  procedures,  under
idazolam  induction  and  propofol  sedation,  a  Pentax  EPK-
000  high-resolution  video  processor  (NJ,  USA)  and  a  Pentax
D-3430  TK  duodenoscope  (NJ,  USA)  with  a  triple  lumen
phincterotome  Wilson  Cook  Medical  Inc.,  Winston  Salem
C,  USA  were  used.  Sphincterotomy  was  performed  in  all
atients.
Blood  samples  from  eligible  patients  undergoing  ERCP
ere  collected  24  h before  (baseline)  and  24  h  after  the
rocedure.  Serum  samples  were  stored  at  −70 ◦C  until  ana-
yzed.  Melatonin  (10  mg)  was  administered  sublingually  in  14
atients  in  ﬁve  doses  (each  8  h  apart),  starting  10  h  before
he  procedure,  up  to  24  h  after  the  ERCP  (total  dose  50  mg).
nother  group  of  16  patients  received  matching  placebo  and
erved  as  controls.
aboratory  examinations
iver  function  tests  (LFTs),  amylase,  TNF-a,  IL-6,  vascular
ndothelial  growth  factor  (VEGF),  and  lipid  peroxidation
ere  measured  in  the  blood  samples  of  all  the  patients.
FTs  and  amylase  were  measured  using  standard  biochemi-
al  methods.  Serum  TNF-alpha,  IL-6,  and  VEGF  levels  were
easured  by  enzyme-linked  immunosorbent  assay  accord-
ng  to  the  manufacturer’s  instructions  (Pre-ProTech  Mexico;
LISA  ASYS  Hitech  GmbH  Expert  Plus  UV  G020151).  Lipid
eroxidation  was  measured  using  a  colorimetric  assay  kit
TBARS  method,  Cayman  Chemicals,  Ann  Arbor,  MI),  which
xpresses  lipid  peroxidation  as  malondialdehyde  (MDA)  con-
entrations.
Asymptomatic  hyperamylasemia  was  deﬁned  as  a  post-
rocedure  value  above  the  upper  normal  limit  (UNL)  of  our
aboratory  (100  IU)  if  the  pre-procedure  value  was  normal,
r  as  any  increase  if  the  pre-procedure  value  was  above  the
NL,  and  if  there  were  no  symptoms  of  AP.
tatistical  methods
he  primary  end  point  was  to  assess  the  effects  of  melatonin
n  post-ERCP-induced  hyperamylasemia  and  elevations  in
nﬂammatory  and  oxidative  stress  markers.  The  secondary
utcome  was  to  determine  the  occurrence  of  post-ERCP
omplications  and  the  effect  on  liver  function  enzymes
etween  groups.
A  restricted  randomization  procedure  was  used  to  con-
rol  the  probability  of  obtaining  an  allocation  sequence  with
n  undesirable  sample  size  imbalance  in  the  intervention
roups.  Blocking  was  used,  utilizing  a  one-to-one  ratio  until  a
otal  of  40  individuals  was  reached,  to  ensure  that  the  groups
ere  the  same  size.  An  outside  individual  not  involved  in
he  care  of  the  trial  patients  and  not  at  the  study  site  was
esponsible  for  the  allocation  and  preparation  of  the  med-
cation  and  its  containers.  Sequentially  numbered,  sealed,
paque  containers  were  used  to  transport  the  drugs.  All  of
he  containers  were  tamper-proof,  equal  in  weight,  and  sim-
lar  in  appearance.  A  nurse  was  in  charge  of  administering
he  medication.  The  medication  consisted  of  5-mg  white
ills  of  similar  size,  shape,  texture,  and  ﬂavor.  Patients  par-
icipating  in  the  trial,  care  providers,  and  those  assessing
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37 patients with a high-probability of
choledocholithiasis scheduled for
ERCP were assessed for
eligibility
Double-blind randomization
14 patients included in the analysis
18 patients in the
melatonin group
Excluded
3 missing dose
1 lack of blood sample
Excluded
1 missing dose
2 ERCP rescheduled
19 patients in the
placebo group
16 patients included in the analysis
llment  algorithms  for  the  patients.
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Table  1  Demographic  characteristics.
Group  Melatonin
n  =  14
Placebo
n  =  16
p
Age,  years  35.3  ±  17.3  36.3  ±  15.3  0.86
Women  (%)  12  (85.7)  14  (87.5)  0.89
BMI (kg/m2)  25.3  ±  4.8  27.3  ±  6.6  0.25
Comorbidities
DM (%)  2  (14.3)  4  (25.0)  0.47
HT (%)  2  (14.3)  2  (12.5)  0.89
Pancreatic
stent (%)
1  (7.1)  2  (12.5)  0.63
Cannulation
attempts
2.1 ±  1.2  2.1  ±  1.3  0.90
Choledo-
cholithiasis
(%)
7 (50.0)  8  (50.0)  1.00
ERCP risk
score
2.6  ±  2.7  1.7  ±  1.8  0.37
Data are shown in absolute values (%) and means ± standard
deviation.
T
c
L
TFigure  1  Screening  and  enro
utcomes  were  blinded  to  the  intervention  assignment.  No
hanges  were  made  to  the  methods  after  trial  commence-
ent.
tatistical  analysis
ll  statistical  analyses  were  assessed  using  the  SPSS  pro-
ram  (SPSS  version  17.0;  SPSS  Inc.,  Chicago,  IL).  Statistical
omparisons  between  the  groups  were  made  using  the  Stu-
ent’s  t  test  (when  variables  were  normally  distributed),  the
ann-Whitney  U  test  (for  non-normally  distributed  varia-
les),  or  the  Wilcoxon’s  test  (two  related  samples),  as
equired.  Other  categorical  variables  (reported  as  percent-
ge  frequency  of  occurrence)  such  as  sex,  hyperamylasemia,
nd  comorbidities  were  compared  using  the  X2 test.  All
arameters  were  then  expressed  as  mean  values  ±  standard
eviation  or  median  and  interquartile  range  (IQR),  as
ppropriate.  A  p  value  <  0.05  was  considered  statistically
igniﬁcant.
esults
atients
rom  March  2013  to  July  2013,  37  patients  with  a  high
robability  of  choledocholithiasis  and  scheduled  for  ERCP
ere  assessed  for  eligibility  (ﬁg.  1).  Seven  patients  were
xcluded,  and  the  remaining  30  eligible  patients  with  a  high
robability  of  choledocholithiasis  were  included.  The  mela-
onin  group  consisted  of  14  patients  with  a  mean  age  of
5.3  ±  17.3  years  and  12  (85.7%)  of  them  were  women.  The
lacebo  group  was  made  up  of  16  patients  with  a  mean  age
f  36.3  ±  15.3  years  and  14  (87.5%)  of  them  were  women.
a
±
v
3BMI: body mass index; DM: diabetes mellitus; ERCP: endoscopic
retrograde cholangiopancreatography; HT: hypertension.
he  rest  of  the  baseline  demographic  characteristics  were
omparable  between  the  two  groups  (table  1).
iver  function  tests
here  was  no  signiﬁcant  difference  between  the  melatonin
nd  placebo  groups  in  the  pre-procedure  values  of  AST  (87.5
 57.8  vs.  85.2  ±  66.9  IU/L,  p  =  0.924),  ALT  (143.4  ±  91.9
s.  144.8  ±  140.8  IU/L,  p  =  0.976),  or  total  bilirubin  (3.4  ±
.1  vs.  2.8  ±  3.1  mg/dL,  p =  0.591).  After  24  h,  a signiﬁcant
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Figure  2  Pre-  ERCP  (dark  bars)  and  post-ERCP  (light  bars)  AST
values  (A),  ALT  values  (B),  and  TBil  values  (C)  in  the  melatonin
and  placebo  groups
Results  are  expressed  as  means,  with  error  bars  representing
the standard  deviation.
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in  the  serum  concentrations  of  IL-6  or  TNF-alpha  after  ERCPALT:  alanine  aminotransferase;  AST:  aspartate  aminotrans-
ferase;  TBil:  total  bilirubin.
decrease  in  the  AST,  ALT,  and  total  bilirubin  values  was  found
only  in  the  melatonin  group  (ﬁg.  2).  However,  there  was  no
difference  between  groups  in  the  post-ERCP  values  of  AST,
ALT,  or  total  bilirubin  (p  >  0.05).
Hyperamylasemia
Seven  (43.7%)  patients  in  the  placebo  group  and  6  (42.8%)  in
the  melatonin  group  developed  hyperamylasemia  as  previ-
ously  deﬁned,  p  =  0.960.  A  signiﬁcant  increase  in  the  median
(IQR)  values  of  amylase  levels  after  ERCP  was  observed  in
both  the  melatonin  (pre-CPRE  54.0  [23.7]  vs.  post-CPRE  87.0
[64.5],  p  =  0.004)  and  the  placebo  (pre-CPRE  101.0  [75.0]
vs.  post-CPRE  107.0  [125.0],  p  =  0.008)  groups.  However,
i
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o  difference  between  the  groups  in  pre-ERCP  or  post-ERCP
mylase  levels  was  recorded  (p  >  0.05).
ytokines  and  lipid  peroxidation
he  complete  results  of  TNF-alpha,  IL-6,  VEGF,  and  lipid
eroxidation  (MDA)  are  shown  in  Table  2.  There  was  no
ifference  between  groups  in  the  pre-procedure  or  post-
rocedure  serum  concentrations  of  any  of  the  markers
tudied,  except  for  the  VEGF  values,  which  were  signiﬁ-
antly  higher  in  the  melatonin  group  compared  with  the
lacebo  group.  Only  a  trend  towards  increased  MDA  (p  =
.09)  was  found  when  comparing  pre-procedure  and  post-
rocedure  levels  in  the  melatonin  group.
One  patient  in  the  placebo  group  developed  post-ERCP
ancreatitis.  No  major  or  minor  adverse  effects  related  to
elatonin  or  placebo  were  recorded  in  this  study.
iscussion
o  the  best  of  our  knowledge,  this  is  the  ﬁrst  prospec-
ive,  randomized,  double-blind,  and  placebo-controlled  trial
valuating  the  effects  of  melatonin  on  pancreatic  inﬂamma-
ion  in  humans  after  ERCP.  We  did  not  ﬁnd  any  differences
n  the  changes  of  inﬂammatory  mediators  at  24  h  after  ERCP
ith  the  use  of  melatonin.  Only  one  patient  developed  post-
RCP  pancreatitis  (in  the  placebo  group),  but  our  study
as  neither  designed  nor  powered  to  ﬁnd  an  effect  on  this
ariable.  Serum  AST,  ALT,  and  bilirubin  levels  were  signif-
cantly  reduced  at  24  h  in  the  melatonin  group  and  not  in
he  placebo  group,  which  could  suggest  a  hepatoprotective
ffect.  However,  the  difference  was  small  and  is  of  uncertain
linical  signiﬁcance.
During  AP,  an  imbalance  between  pro-inﬂammatory
nd  anti-inﬂammatory  mediators,  cytokine  release,  and
ncreased  oxidative  stress  participate  as  effectors  of  local
nd  systemic  injury.8,20 These  inﬂammatory  alterations,  as
ell  as  different  degrees  of  hyperamylasemia,  are  also  asso-
iated  with  ERCP  and  its  related  complications.  In  a  study
f  70  patients  undergoing  ERCP,  early  (within  24  h)  serum
levations  of  IL-6  and  C-reactive  protein  occurred  in  those
atients  that  developed  post-ERCP  pancreatitis.4 Another
tudy  of  45  patients  undergoing  ERCP  showed  similar  results,
ith  early  elevations  of  IL-6  and  TNF-alpha  occurring  in
atients  with  complications.6
We  studied  a  homogeneous  group  of  low-risk  patients
ccording  to  the  Friedland  score,19 under  the  assumption
hat  even  in  asymptomatic  cases,  stimulation  of  the  inﬂam-
atory  cascade  during  ERCP  could  be  the  initial  signal
esponsible  for  the  development  of  complications  such  as
ancreatitis.  This  paradigm  could  be  used  to  study  both
he  acute  phase  response  and  relevant  therapeutic  inter-
entions.  In  experimental  models  that  could  partially  mimic
ome  of  the  alterations  associated  with  ERCP,  bile  duct  liga-
ion  induced  cholestatic  liver  injury  and  increased  oxidative
tress,  and  these  changes  were  ameliorated  by  melatonin.21
owever,  in  our  study  we  did  not  observe  relevant  changesn  either  the  treatment  or  the  placebo  groups.  We  found
ower  pre-procedure  and  post-procedure  levels  of  VEGF  in
he  placebo  group,  compared  with  the  melatonin  group,  but
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Table  2  Cytokines  and  lipid  peroxidation.
Group  Melatonin
n  =  14
Placebo
n  =  16
pre-ERCP
n  =14
post-ERCP
n  =14
pre-ERCP
n  =  16
post-ERCP
n  =  16
TNF-alpha  (ng/mL) 153.8  ±  11.3 149.4  ±  12.1 103.5  ±  53.4 107.3  ±  53
IL-6 (ng/mL)  131.8  ±  44.9  133.3  ±  44.7  177.8  ±  204.0  197.8  ±  246.8
MDA (g/mL)  39.2  ±  16.8  72.3  ±  50.8a 66.4  ±  66.3  90.5  ±  78
VEGF (pg/mL)  157.3  ±  36.5  157.8  ±  39.4  97.3  ±  45.9b 97.8  ±  47.9c
Data are shown in means ± standard deviation.
ERCP: endoscopic retrograde cholangiopancreatography; IL: interleukin; MDA: malondialdehyde; TNF: tumor necrosis factor; VEGF:
vascular endothelial growth factor.
a p = 0.09 vs. pre-ERCP MDA.
b p < 0.01 vs. melatonin group.
c
n
E
b
i
r
b
c
i
I
p
t
o
A
t
i
c
t
r
a
m
m
b
w
a
p
a
6
h
w
c
i
c
i
i
t
r
o
n
s
t
a
t
r
m
i
e
a
a
l
e
m
t
i
r
t
r
b
m
m
i
a
c
a
t
a
a
m
t
H
m
d
d
g
e
E
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o  changes  within  the  groups  that  could  be  attributed  to
RCP  or  to  an  effect  of  melatonin.  Serum  VEGF  is  known  to
e  increased  in  experimental  models  of  acute  pancreatitis
n  rats,22 and  melatonin  could  increase  VEGF  expression  in  a
at  model  of  gastric  ulcer  healing.23 However,  melatonin  has
een  shown  to  reduce  VEGF  expression  in  a  variety  of  human
ells,  including  pancreatic  and  liver  cancer  cells,  mak-
ng  a  melatonin-dependent  effect  unlikely  in  our  study.24,25
nadequate  dosing  and  a  single  observation  period  (24  h  post-
rocedure)  could  also  account  for  our  negative  results.
The  only  variables  that  appeared  to  be  affected  by  mela-
onin  in  our  study  were  ALT,  AST,  and  total  bilirubin,  each
f  which  had  a  reduction  in  their  post-procedure  levels.
lthough  we  speculate  that  the  post-ERCP  decreases  in
hese  parameters  could  indicate  resolution  of  cholestasis-
nduced  hepatocellular  injury,  this  ﬁnding  is  of  unknown
linical  signiﬁcance.  However,  melatonin  receptors  exist  in
he  liver  and  melatonin  administration  has  been  shown  to
educe  cholestasis-induced  hepatocellular  injury,  as  well
s  transaminase  and  bilirubin  elevations,  in  experimental
odels  of  bile  duct  ligation.26,27 Sequential  measure-
ent  studies  or  inclusion  of  high-risk  patients  would
e  needed  to  conﬁrm  a  biochemical  beneﬁt,  if  there
ere  one.
Melatonin  at  therapeutic  and  physiologic  doses  acting
s  a  free  radical  scavenger  reduces  every  step  in  lipid
eroxidation  and  promotes  the  production  of  endogenous
ntioxidants.  It  also  reduces  production  of  TNF-alpha,  IL-
,  prostaglandins,  and  nitric  oxide  (NO).28 Toxicity  studies
ave  shown  that  exogenous  melatonin  is  safe  and  tolerable,
ith  no  discernible  toxic  or  dose-limiting  effects.12 Clini-
al  studies  have  been  published  that  explore  melatonin’s
mmunomodulatory  properties.  Melatonin  could  reduce  cir-
ulating  levels  of  NO  and  pro-inﬂammatory  cytokines
n  septic  neonates,  changes  that  were  accompanied  by
mproved  outcomes.13 In  adult  patients  that  underwent  aor-
ic  surgery,  perioperative  melatonin  was  associated  with
educed  levels  of  oxidative  stress.14 In  our  study,  we
bserved  no  peri-anesthetic  side  effects  or  excessive  drowsi-
ess,  and  we  concluded  that  melatonin  administration  was
afe  and  tolerable,  in  accordance  with  other  human  studies
hat  have  used  similar  doses.29
n
s
c
aOur  negative  results  are  surprising  in  light  of  the
vailable  indirect  evidence.  A  physiologic  role  for  mela-
onin  in  pancreatic  function  has  been  proposed.  Melatonin
eceptors  exist  in  pancreatic  tissue  and  melatonin  can
odulate  pancreatic  secretion  and  blood  ﬂow.17 In  exper-
mental  models,  the  protective  effects  of  melatonin  are
nhanced  at  night,  corresponding  to  the  circadian  rhythm
nd  higher  endogenous  levels  of  melatonin.30 Additionally,
 recent  study  showed  that  low  endogenous  melatonin
evels  in  patients  with  AP  correlated  with  increased  dis-
ase  severity.31 There  are  also  studies  that  suggest  that
elatonin  might  be  pancreatoprotective.  Qi  et  al.  were
he  ﬁrst  to  show  that  melatonin  could  reduce  tissue
njury  in  an  experimental  model  of  cerulein-induced  AP  in
ats.16 The  increase  in  endogenous  levels  of  melatonin  led
o  reduction  of  cerulein-induced  AP  severity,  as  well  as
eductions  in  TNF-alpha.32 Melatonin  supplementation  has
een  shown  to  induce  reductions  in  tissue  injury,  inﬂam-
atory  markers,  and  multiorgan  failure  in  other  animal
odels  of  AP,  such  as  L-arginine  administration,33 pancreatic
schemia-reperfusion  injury,34 pancreatic  duct  ligation,35
nd  taurocholate  administration.36 Reductions  in  free  radi-
al  production,  lipid  peroxidation,  and  mitochondrial  injury
nd  increases  in  endogenous  antioxidants,  such  as  glu-
athione,  have  also  been  demonstrated  in  models  of  AP
fter  melatonin  administration.37 Other  studies  on  AP  have
lso  shown  modulation  of  TNF-alpha  and  IL-1  production  by
elatonin.38 Melatonin  appears  to  be  pancreatoprotective
hrough  the  modulation  of  multiple  inﬂammatory  pathways.
owever,  we  did  not  ﬁnd  evidence  that  melatonin  could
odulate  inﬂammatory  cytokine  production  or  lipid  peroxi-
ation  in  the  context  of  ERCP.
Limitations  in  our  study  design  could  well  explain  this
iscrepancy,  such  as  single  dose,  small  sample  size,  sin-
le  measurement  of  biochemical  variables,  and  biochemical
nd-points  (instead  of  clinical  endpoints,  such  as  post-
RCP  pancreatitis).  Melatonin  does  appear  to  be  safe  and
olerable  (no  reported  adverse  events  or  excessive  drowsi-
ess)  in  patients  undergoing  ERCP,  but  we  did  not  ﬁnd  a
igniﬁcant  effect  of  melatonin  on  inﬂammatory  cytokine
oncentrations  or  lipid  peroxidation  at  the  dose  studied.  The
pparently  beneﬁcial  effect  on  transaminases  and  bilirubin
socia
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2Effects  of  melatonin  on  the  acute  inﬂammatory  response  as
are  of  unknown  signiﬁcance.  Large  clinical  trials  using  dif-
ferent  doses  and  periods  of  evaluation,  as  well  as  different
(high-risk)  populations,  are  warranted  to  determine  if  mela-
tonin  can  reduce  the  incidence  of  post-ERCP  pancreatitis  or
AP  severity.
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